# A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

> **NCT03254784** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 49 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Arthritic Psoriasis
- Psoriasis
- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** BMS-986165 Capsule
- **DRUG:** BMS-986165 Tablet

## Key facts

- **NCT ID:** NCT03254784
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-13
- **Primary completion:** 2017-11-04
- **Final completion:** 2017-11-15
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254784, "A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03254784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*